title: Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial.
abstract: BACKGROUND
  Colchicine seems to be a good drug for treating recurrences of pericarditis after conventional treatment failure, but no clinical trial has tested the effects of colchicine as first-line drug for the treatment of the first recurrence of pericarditis.
  
  
  METHODS
  A prospective, randomized, open-label design was used to investigate the safety and efficacy of colchicine therapy as adjunct to conventional therapy for the first episode of recurrent pericarditis. Eighty-four consecutive patients with a first episode of recurrent pericarditis were randomly assigned to receive conventional treatment with aspirin alone or conventional treatment plus colchicine (1.0-2.0 mg the first day and then 0.5-1.0 mg/d for 6 months). When aspirin was contraindicated, prednisone (1.0-1.5 mg/kg daily) was given for 1 month and then was gradually tapered. The primary end point was the recurrence rate. Intention-to-treat analyses were performed by treatment group.
  
  
  RESULTS
  During 1682 patient-months (mean follow-up, 20 months), treatment with colchicine significantly decreased the recurrence rate (actuarial rates at 18 months were 24.0% vs 50.6%; P = .02; number needed to treat = 4.0; 95% confidence interval 2.5-7.1) and symptom persistence at 72 hours (10% vs 31%; P = .03). In multivariate analysis, previous corticosteroid use was an independent risk factor for further recurrences (odds ratio, 2.89; 95% confidence interval, 1.10-8.26; P = .04). No serious adverse effects were observed.
  
  
  CONCLUSIONS
  Colchicine therapy led to a clinically important and statistically significant benefit over conventional treatment, decreasing the recurrence rate in patients with a first episode of recurrent pericarditis.
authors.affiliation: Cardiology Department, Maria Vittoria Hospital, Torino, Italy. massimo_imazio@yahoo.it
authors.forename: Massimo
authors.initials: M
authors.lastname: Imazio
authors.forename: Marco
authors.initials: M
authors.lastname: Bobbio
authors.forename: Enrico
authors.initials: E
authors.lastname: Cecchi
authors.forename: Daniela
authors.initials: D
authors.lastname: Demarie
authors.forename: Franco
authors.initials: F
authors.lastname: Pomari
authors.forename: Mauro
authors.initials: M
authors.lastname: Moratti
authors.forename: Aldo
authors.initials: A
authors.lastname: Ghisio
authors.forename: Riccardo
authors.initials: R
authors.lastname: Belli
authors.forename: Rita
authors.initials: R
authors.lastname: Trinchero
mesh_terms: D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D003078:Colchicine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010493:Pericarditis / Q000188:drug therapy*; D011241:Prednisone / Q000627:therapeutic use; D011446:Prospective Studies; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D001241:Aspirin; D003078:Colchicine; D011241:Prednisone